1-4 of 4
Doen Ming Ong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Clinical Trials & Observations
Sun Loo, Andrew W. Roberts, Natasha S. Anstee, Glen A. Kennedy, Simon He, Anthony P. Schwarer, Anoop K. Enjeti, James D’Rozario, Paula Marlton, Ian A. Bilmon, John Taper, Gavin Cull, Campbell Tiley, Emma Verner, Uwe Hahn, Devendra K. Hiwase, Harry J. Iland, Nick Murphy, Sundra Ramanathan, John Reynolds, Doen Ming Ong, Ing Soo Tiong, Meaghan Wall, Michael Murray, Tristan Rawling, Joanna Leadbetter, Leesa Rowley, Maya Latimer, Sam Yuen, Stephen B. Ting, Chun Yew Fong, Kirk Morris, Ashish Bajel, John F. Seymour, Mark J. Levis, Andrew H. Wei
Journal: Blood
Blood (2023) 142 (23): 1960–1971.
https://doi.org/10.1182/blood.2023020301
Published: 2023
Includes: Supplemental data
Journal Articles

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Natasha S Anstee, PhD, Giovanna Pomilio, Mark Levis, MD PhD, Sarah MacRaild, Michael Murray, PhD DSc, Tristan Rawling, PhD, Glen A Kennedy, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Anthony Schwarer, MBBS, MD FRACP, FRCPA, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, James D'Rozario, MBBS, FRACP, FRCPA, Paula Marlton, MBBS FRACP FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Adam Ivey, BSc, MSc, PhD, Doen Ming Ong, MBBS, Andrew W Roberts, MBBS, Andrew H Wei, MBBS, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–18.
https://doi.org/10.1182/blood-2020-141711
Published: 2020
Journal Articles

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Andrew H Wei, MBBS, PhD, Glen A Kennedy, MBBS FRACP FRCPA, Kirk L Morris, MBBA, FRACP, FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Simon He, MBBS, FRACP, FRCPA, Anthony Schwarer, MBBS, MD FRACP, FRCPA, Stephen B Ting, MBBS, FRACP, FRCPA, PhD, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, Sam Yuen, MBBS, FRACP, FRCPA, James D'Rozario, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Paula Marlton, MBBS FRACP FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, John Taper, MBBS, FRACP, FRCPA, B Pharm, Gavin Cull, MBBS, MD FRACP, FRCPA, Campbell Tiley, MBBS, FRACP, FRCPA, Emma Verner, MBBS, FRACP, FRCPA, Uwe H Hahn, MBBS, MD FRCPA, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Harry Iland, MBBS, FRACP, FRCPA, MHGSA, Nichloas Murphy, MBBS, FRACP, FRCPA, Sundra Ravanathan, MBBS, FRACP, FRCPA, RCPA, Uyen Nguyen, Doen Ming Ong, MBBS, FRACP, FRCPA, RCPA, Sun Loo, MBBS, FRACP, FRCPA, RCPA, Ing-Soo Tiong, MBBS, FRACP, FRCPA, RCPA, Meaghan Wall, MBBS, FRACP, FRCPA, RCPA, PhD, Natasha S Anstee, PhD, Mark Levis, MD PhD, Michael Murray, PhD DSc, Tristan Rawling, PhD, Joanna Leadbetter, PhD, Ashish Bajel, FRACP, Andrew W Roberts, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–38.
https://doi.org/10.1182/blood-2020-137334
Published: 2020
Journal Articles

Clinical Relevance of Partial Response in the Marrow (PRm) after Failure of Frontline Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML)

Shaun Fleming, MBBS (Hons), FRACP, FRCPA, Doen Ming Ong, MBBS, Kathryn Jackson, MBBS, FRACP, FRCPA, Sharon Avery, MBBS (Hons), FRACP, FRCPA, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Paula Marlton, MBBS, FRACP, FRCPA, Glen A Kennedy, MBBS, FRACP, FRCPA, Andrew Wei, MBBS, FRACP, FRCPA, PhD
Journal: Blood
Blood (2015) 126 (23): 2512.
https://doi.org/10.1182/blood.V126.23.2512.2512
Published: 2015